FDA Grants 501K Clearance to Bladder EpiCheck for Surveillance in NMIBC
The FDA has granted 510K clearance to Bladder EpiCheck for use as a noninvasive method for surveillance of tumor recurrence in previously diagnosed patients with non–muscle invasive bladder cancer, in conjunction with cystoscopy.
Source: onclive.com
